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Trisomy 21 (Ts21) causes deficits in motor and cognitive ability that are hallmark phenotypes in 
Down syndrome (DS). The Ts65Dn mouse model of DS has about 50% of the orthologous genes 
that are triplicated from human chromosome 21, including the Dual specificity tyrosine-
phosphorylation-regulated kinase 1A (Dyrk1A) gene. Three copies of Dyrk1A have been 
implicated in the motor and cognitive deficits and altered cerebellar structure and function may 
contribute these impairments in Ts65Dn mice. Epigallocatechin 3-gallate (EGCG) is a catechin 
found in green tea and an inhibitor of Dyrk1A activity. We hypothesize that a 200mg/kg EGCG 
treatment given by oral gavage will inhibit Dyrk1A activity in the cerebellum of Ts65Dn mice 
and rescue deficits in motor coordination while performing the balance beam task. Evidence of 
improvement in this task would be observed as a reduction of paw slips as the animal traverses 
across beams of varying widths.  In previous studies, EGCG treatment was placed in the 
animal’s water to be consumed but EGCG rapidly degrades in solution and it is difficult to 
control treatment doses via treatment in drinking water, due to each animal’s consumption 
behavior. This study utilized a daily oral gavage treatment of EGCG to control the dose and 
limits loss due to degradation. Results to date indicate that the Ts65Dn mice show deficits on the 
balance beam task relative to the euploid mice, particularly at the narrowest beam width used.  
The EGCG treatment does not appear to improve the performance of the Ts65Dn mice, though 
the lack of observed effects of EGCG may be due to the relatively low numbers of Ts65Dn-
EGCG treated mice that have completed testing so far. One notable trend is that we will continue 
to test additional mice to gain sufficient power to determine conclusively whether EGCG 
improves motor coordination performance in Ts65Dn mice.  
 
 
 
 
 
 
 
 
 
